Trends in Molecular Medicine
SpotlightLearning from PD-1 Resistance: New Combination Strategies
Section snippets
Acknowledgments
Research Support: DF/HCC Kidney Cancer SPORE P50CA101942 (G.J.F.). Research supported by Claudia Adams Barr Program for Innovative Cancer Research (K.M.).
References (10)
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
Cell
(2016)Non-genomic and immune evolution of melanoma acquiring MAPKi resistance
Cell
(2015)MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
Immunity
(2016)Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer
Clin. Cancer Res.
(2015)Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Nat. Commun.
(2016)
Cited by (54)
The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors
2022, Pharmacology and TherapeuticsCitation Excerpt :Subsequent analyses showed that the combination of the interferon pathway activity and IPRES-related immunosuppressive stromal scores are accurate predictors of ICB response in melanoma, gastric and metastatic urothelial carcinoma (Cui et al., 2021; Jiang et al., 2018; Zeng et al., 2021). The biological processes under IPRES were dominated by angiogenesis, hypoxia, epithelial to mesenchymal transition (EMT), and extracellular matrix remodeling, all of which are immunosuppressive processes related to the TGF-β and VEGFA pathways (Bu et al., 2016; MacCarthy-Morrogh & Martin, 2020; Parayath, Padmakumar, Nair, Menon, & Amiji, 2020; Schäfer & Werner, 2008). Therapeutic agents targeting TGF-β and VEGFA, the representative pathways of IPRES, may synergize with existing immunotherapies to overcome ICB resistance.
Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer
2021, BiomaterialsCitation Excerpt :Clinical efficacy of immune checkpoint inhibitors (ICIs) has exhibited unprecedented results in the recent years, however, they have shown to generate no effectual responses against tumors with low active host immunity [1].
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
2019, Progress in Molecular Biology and Translational ScienceTargeting T regulatory (T<inf>reg</inf>) cells in immunotherapy-resistant cancers
2024, Cancer Drug Resistance
- 3
Co-first authors.